Proteomic Biomarkers for Lung Cancer Progression

Ren, Yanjiao; Zhao, Shuhong; Jiang, Dandan; Feng, Xin; Zhang, Yexian; Wei, Zhipeng; Wang, Zhongyu; Zhang, Wenniu; Zhou, Qing; Li, Yong; Hou, Hanxu; Xu, Ying; Zhou, Fengfeng

doi:10.2217/bmm-2018-0015

Cited by 8 publications

(5 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, about 20.00% of stage I patients undergone radical resection still have local recurrence or distant metastasis (3). Though much effort has been reported in searching for biomarkers that aid in predicting the prognosis of patients with early lung adenocarcinomas (4,5), tumor size is still an irreplaceable prognostic factor, especially in the newly published 8 th edition of the American Joint Committee on Cancer (AJCC) Staging Manual lung cancer staging system, which emphasizes much more on each centimeter increase in tumor size (6,7).…”

Section: Introductionmentioning

confidence: 99%

Spread through air spaces predicts a worse survival in patients with stage I adenocarcinomas >2 cm after radical lobectomy

Yang

et al. 2018

J. Thorac. Dis

View full text Add to dashboard Cite

Background: The aim of this study was to evaluate the significance of spread through air spaces (STAS) in early lung adenocarcinomas after radical lobectomy and lymphadenectomy. Methods: A total of 242 patients with lung adenocarcinomas less than 4 cm (8th pStage I) were selected from the lung cancer patients surgically treated from January, 2009 to September, 2011. Pathological review focused on STAS as well as histological subtypes, blood vessel & neural invasion, pathological tumor size etc. Recurrence or disease-free survival (DFS) and overall survival (OS) were compared between patients as stratified by STAS and tumor size. Results: STAS was observed in 33.47% (81/242) patients, which was significantly correlated with histological predominant subtype (χ 2 =25.903, P=0.093×10 −3) and differentiation grade (χ 2 =23.986, P=0.025×10 −3). Patients with STAS (+) showed a comparable PFS (P=0.268) and OS rates (P=0.100) in all stage I cases, but a significant lower PFS (P=0.029) and OS (P=0.013) in tumors within 2< tumors ≤4 cm. Multivariate analysis revealed STAS to be an independent worse prognostic factor in lung adenocarcinomas within 2< tumors ≤4 cm, both for PFS (P=0.004) and OS (P=0.002) , while no significant difference was found in patients with tumors ≤2 cm (PFS, P=0.537; OS, P=0.448), after adjusting by other clinicopathological parameters as age, gender, smoking etc. Conclusions: Presence of STAS was a significant worse predictor for pStage I patients with lung adenocarcinoma >2 cm who underwent radical lobectomy, while it is not significant in patients with tumor ≤2 cm. These findings may be helpful in assessing postoperative therapy stratified by tumor size and STAS status.

show abstract

Section: Introductionmentioning

confidence: 99%

Spread through air spaces predicts a worse survival in patients with stage I adenocarcinomas >2 cm after radical lobectomy

Yang

et al. 2018

J. Thorac. Dis

View full text Add to dashboard Cite

show abstract

“…However, despite advances in the diagnosis and treatment of LUAD, the OS time of patients with LUAD remains poor (29). Recent studies have identified molecular biomarkers throughout the various clinical stages and pathological tissue types (30,31). However, patients with the same clinical and pathological features at diagnosis often have a completely different final prognoses (32).…”

Section: Discussionmentioning

confidence: 99%

Identification of a long non‑coding RNA signature for predicting prognosis and biomarkers in lung adenocarcinoma

Zhang

2020

Oncol Lett

View full text Add to dashboard Cite

Long non-coding RNAs (lncRNAs) have a number of functions in various cellular processes and are potential prognostic factors for lung adenocarcinoma (LUAD). A gene risk model could provide novel evidence to improve the prediction of overall outcomes and provide more potential biomarkers. The present study aimed improve a previously published method of gene signature construction to make it more robust and accurate. The lncRNA expression profiles from 594 patients with LUAD were obtained from The Cancer Genome Atlas (TCGA) database and samples were divided into high-and low-risk groups based on median risk scores calculated using a prognosis-related risk score formula. Univariate Cox regression, least absolute shrinkage and selection operator algorithm and multivariate Cox regression were performed to construct a gene signature based on the differentially expressed lncRNAs in patients with LUAD. The robustness and accuracy of the present model was assessed using area under the calculated curves (AUC) and Kaplan-Meier (K-M) survival analysis of the high-and low-risk cohorts. Potential biomarkers associated with survival status were then identified using K-M survival analysis and potential biomarker functions were predicted using enrichment analysis of co-expressed mRNAs. The gene signature constructed contained 44 lncRNAs. The AUCs for 3-and 5-year survival with the model were 0.836 and 0.818, respectively, of a time-dependent receiver operator characteristic curve. Moreover, lncRNAs AC124804.1 and MIR34AHG were identified using K-M survival analysis and the potential function of these two lncRNAs was predicted using Gene Ontology and Kyoto Encyclopedia of Genes and Genomes functional enrichment. The present lncRNA model provides novel insight which may improve prediction of prognosis for patients with LUAD and identify potentially novel biomarkers for the diagnosis.

show abstract

“…[2] Lung adenocarcinoma (LUAD) is the main subtype of NSCLC and accounts for two-thirds of all lung cancer patients. [3,4] No obvious clinical symptoms in the early stage cause a considerable proportion of LUAD patients to be diagnosed at an advanced stage. [5] Hence, the best therapeutic strategy is to seek effective markers for early diagnosis and treatment of LUAD.…”

Section: Introductionmentioning

confidence: 99%

Silencing of circ_0088036 inhibits growth and invasion of lung adenocarcinoma through miR‐203/SP1 axis

Liu,

Feng,

Wang

et al. 2024

J Biochem & Molecular Tox

View full text Add to dashboard Cite

Lung cancer is the leading cause of cancer‐related deaths worldwide. Circular RNA (circRNA) circ_0088036 is a recently discovered circRNA known for its roles in rheumatoid arthritis. The study aimed to study the function of circ_0088036 in lung adenocarcinoma (LUAD). Circ_0088036 expressions were analyzed in the Gene Expression Omnibus (GEO) database. The relationship between circ_0088036 expressions and clinicopathological data of LUAD was assessed. The messenger RNA and protein levels were analyzed by quantitative real‐time polymerase chain reaction and Western blot. Cell viability, apoptosis, and invasion were tested by Cell Counting Kit‐8, flow cytometry, and transwell assay. The direct interaction between microRNA‐203 (miR‐203) and circ_0088036 or specificity protein 1 (SP1) was confirmed by dual‐luciferase reporter assay, RNA pull‐down, and RNA immunoprecipitation assays. Circ_0088036 was overexpressed in LUAD from the analysis of the GEO database. The poor prognosis was found in the patients with high expressions of circ_0088036. The level of Circ_0088036 was increased in LUAD tissues and cells. In terms of function, the deletion of circ_0088036 inhibited LUAD tumorigenesis in vitro by repressing cell growth, invasion, and epithelial–mesenchymal transition (EMT). In mechanism, circ_0088036 could competitively sponge miR‐203, thereby affecting the expressions of the target gene SP1. In addition, lessening of miR‐203 and enlarging of SP1 could eliminate the anticancer effect of short hairpin RNA‐circ_0088036 on LUAD cells. Besides, the knockout of circ_0088036 hindered the growth of xenografted tumors in vivo. Circ_0088036 promoted the LUAD cell growth, invasion, and EMT via modulating the miR‐203/SP1 axis in LUAD.

show abstract

Proteomic Biomarkers for Lung Cancer Progression

Abstract: A comparative analysis was also carried out on related transcriptomic datasets, which indicates that the proposed biomarkers provide discerning power for accurate stage prediction, and will be improved when larger-scale proteomic quantitative technologies become available.

Cited by 8 publications

References 62 publications

Spread through air spaces predicts a worse survival in patients with stage I adenocarcinomas >2 cm after radical lobectomy

Spread through air spaces predicts a worse survival in patients with stage I adenocarcinomas >2 cm after radical lobectomy

Identification of a long non‑coding RNA signature for predicting prognosis and biomarkers in lung adenocarcinoma

Silencing of circ_0088036 inhibits growth and invasion of lung adenocarcinoma through miR‐203/SP1 axis

Contact Info

Product

Resources

About